SHR-A2102

Phase 3Small molecule

Shanghai Hengrui Pharmaceutical Co., Ltd.

SHR-A2102 is one of 261 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

260

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerRecruiting

Breast CancerNot yet recruiting

Solid TumorRecruiting

Advanced Breast CancerRecruiting

Advanced Solid TumorsRecruiting

Advanced Gynecological MalignancyRecruiting

Patients With Advanced Solid TumorsRecruiting

Recurrent/metastatic Head and Neck Squamous Cell CarcinomaRecruiting

Phase IBNot yet recruiting

Urothelial CarcinomaRecruiting

Non-Small Cell Lung CancerPhase 2

Recruiting

Breast CancerPhase 2

Not yet recruiting

Solid TumorPreclinical

Recruiting

Advanced Breast CancerPhase 2

Recruiting

Advanced Solid TumorsPhase 2

Recruiting

Advanced Gynecological MalignancyPhase 2

Recruiting

Patients With Advanced Solid TumorsPhase 1

Recruiting

Recurrent/metastatic Head and Neck Squamous Cell CarcinomaPreclinical

Recruiting

Phase IBPhase 1

Not yet recruiting

Urothelial CarcinomaPhase 3

Recruiting

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

SHR-A2102

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 3

2 2

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 3

Vfend

PPrism Pharmaceuticals

Preclinical

—4

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 5

Tianeptine

Pfizer

Preclinical

1 6

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 7

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

2 8

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 9

4SCAR T Cells

SShenzhen Geno-Immune Medical Institute

Preclinical

1 10

QBX258

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Breast Cancer

NCT05594095

Q1 2027

Phase 2Not yet recruiting

Breast Cancer

NCT07041437

Phase 2Recruiting

Triple-Negative Breast Cancer

NCT05076682

Q2 2027

Phase 1/2Recruiting

Urothelial Carcinoma

NCT06639347

Q3 2027

Phase 3Recruiting

Urothelial Carcinoma

NCT06738251

Phase 2Recruiting

Advanced Breast Cancer

NCT06649331

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 1/2·NCT06512051·248 enrolled

A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 1/2·NCT06589778·124 enrolled

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 2·NCT07229729·300 enrolled

Advanced Solid Tumors2 trials

A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.

Unknown status· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 1·NCT05735275·252 enrolled

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 2·NCT06895928·400 enrolled

Urothelial Carcinoma2 trials

A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 3·NCT06738251·402 enrolled

A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 1/2·NCT06639347·90 enrolled

Breast Cancer2 trials

Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT07041437·48 enrolled

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting·FFudan University·Phase 2·NCT05594095·620 enrolled

Advanced Breast Cancer2 trials

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer：A Prospective, Open-label, Phase 2 Trial

Recruiting·FFudan University·Phase 2·NCT06649331·160 enrolled

A Phase II Study of Antibody-Drug Conjugates (ADCs) Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Recruiting·BBeijing GoBroad Hospital·Phase 2·NCT06433609·113 enrolled

7 more indications

Advanced Gynecological Malignancy1 trial

A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 2·NCT06654440·100 enrolled

Cervical Cancer1 trial

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

Not yet recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT07418749·398 enrolled

Phase IB1 trial

A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

Not yet recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT07414953·400 enrolled

Patients With Advanced Solid Tumors1 trial

Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 1·NCT05701709·395 enrolled

Triple-Negative Breast Cancer1 trial

Reverse Triple Negative Immune Resistant Breast Cancer

Recruiting·FFudan University·Phase 2·NCT05076682·90 enrolled

Solid Tumor1 trial

A Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With or Without Antitumor Therapy in Subjects With Advanced Solid Tumors

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Preclinical·NCT06417554·80 enrolled

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma1 trial

A Multicenter, Open-label Phase Ib/II Clinical Trial of SHR-A2102 Injection in Combination With Adebrelimab Injection, With or Without Other Anti-tumor Therapies, in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Preclinical·NCT07059221·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for SHR-A2102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR-A2102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR-A2102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Hengrui Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Shanghai Hengrui Pharmaceutical Co., Ltd.

SHR-A2102

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Advanced Solid Tumors2 trials

Urothelial Carcinoma2 trials

Breast Cancer2 trials

Advanced Breast Cancer2 trials

Advanced Gynecological Malignancy1 trial

Cervical Cancer1 trial

Phase IB1 trial

Patients With Advanced Solid Tumors1 trial

Triple-Negative Breast Cancer1 trial

Solid Tumor1 trial

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News